Lv1
10 积分 2023-07-26 加入
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
2小时前
待确认
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
8天前
已完结
Adjuvant Immunotherapy Does Not Improve Survival in Non-small Cell Lung Cancer with Major/Complete Pathological Response after Induction Immunotherapy
9天前
已完结
MA19.08 Transcriptomic Features of Circulating CX3CR1+CD8+ Temra Cells as a Predictor of Chemo-Immunotherapy Response in NSCLC Patients
1个月前
已关闭
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
1个月前
已完结
SUMOylation and DeSUMOylation: Prospective therapeutic targets in cancer
1个月前
已完结
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
2个月前
已完结
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
2个月前
已完结
A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population
2个月前
已完结
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
2个月前
已完结
皖公网安备34019202002308
